| June 1 |
FDA Approves Norditropin for Treatment of Short Stature Associated
with a Rare Genetic Disorder |
|
| June 5 |
Date of Approval: June 4, 2007 Treatment for Postmenopausal Symptoms Divigel is a low dose topical estrogen gel, which is applied to the skin of the thigh once daily for the treatment of moderate to severe hot flashes associated with menopause. FDA Approves Divigel (estradiol gel) 0.1 Percent for Treatment of
Moderate to Severe Hot Flashes Associated with Menopause |
|
| June 6 |
Copaxone Pre-Filled Syringe Can Now Be Stored for up to One Month
at Room Temperature |
|
| June 13 |
Novartis Gains European Approval for Its Innovative Flu Vaccine
Optaflu |
|
| June 13 |
Date of Approval: June 12, 2007 Company: Stiefel Laboratories, Inc. Treatment for Seborrheic Dermatitis Extina Foam is a topical formulation of the antifungal ketoconazole in VersaFoam for the treatment of seborrheic dermatitis. FDA Approves Extina for the Treatment of Seborrheic Dermatitis |
|
| June 15 |
New Dosage Regimen: April 12, 2007
FDA Approves New Route of Administration for Rapid-Acting Apidra
Providing an Additional Treatment Option for Hospitalized Diabetes
Patients with High Blood Sugar Levels |
|
| June 18 |
Date of Approval: June 15, 2007 Company: Gilead Sciences, Inc. Treatment for Pulmonary Hypertension Letairis is an endothelin receptor antagonist (ERA) indicated for the once-daily oral treatment of pulmonary arterial hypertension. U.S. Food and Drug Administration Approves Gilead's Letairis
(ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment
of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with
WHO Functional Class II or III Symptoms |
|
| June 18 |
Date of Approval: June 15, 2007 Company: Cephalon, Inc. Treatment for Excessive Sleepiness Nuvigil is a non-amphetamine wake-promoting agent for the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), narcolepsy, and shift work sleep disorder (SWSD). Cephalon Receives FDA Approval of Nuvigil for the Treatment of
Excessive Sleepiness Associated with Three Disorders |
|
| June 18 |
FDA Approves New Orphan Drug Letairis for Treatment of Pulmonary Arterial
Hypertension |
|
| June 19 |
The International Myeloma Foundation Says EMEA Marketing Approval
of Revlimid is an Important Advance for Patients in Europe |
|
| June 20 |
FDA Approves Differin (adapalene) Gel, 0.3% for Acne |
|
| June 21 |
Exforge (amlodipine and valsartan) Tablets Date of Approval: June 20, 2007 Company: Novartis Treatment for Hypertension Exforge is a single-tablet combination of an angiotensin receptor blocker (valsartan) and a calcium channel blocker (amlodipine) taken once-daily for the treatment of hypertension. Exforge Receives Final US Approval as New and Powerful Treatment
Option for Patients With High Blood Pressure |
|
| June 21 |
King Pharmaceuticals Announces FDA Approval of Epistaxis Kit for
Thrombin-JMI |
|
| June 22 |
Date of Approval: June 21, 2007 Company: Ferring Pharmaceuticals, Inc. Treatment for Female Infertility Endometrin is a progesterone vaginal insert indicated to support embryo implantation and early pregnancy as part of an Assisted
Reproductive Technology (ART) treatment for infertile women. FDA Approves Ferring Pharmaceuticals' Endometrin for Luteal Phase
Support in Assisted Reproductive Technology Treatment |
|
| June 22 |
FDA Approves First Drug for Treating Fibromyalgia - Lyrica |
|
| June 22 |
Ranbaxy Receives Tentative Approval for Tamsulosin Capsules |
|
| June 22 |
FDA Approves Carnitor SF (Levocarnitine) Sugar-Free Oral Solution
For Patients With Carnitine Deficiency |
|
| June 25 |
Genzyme Receives FDA Approval for New Labeling for Carticel |
|
| June 26 |
Allergan Announces FDA Approval of Label Extensions for Juvederm
Ultra and Juvederm Ultra Plus |
|
